Abstract
Objective: To describe the effects of intra-ovarian platelet-rich plasma injection on the ovarian stimulation outcomes in women referring to an in vitro fertilization center. Method: We conducted a single-center retrospective study on 179 women that underwent intra-ovarian platelet-rich plasma injection over the last three years. Inclusion criteria included women over age 35 with at least one ovary with a history of infertility, hormonal abnormalities, absence of menstrual cycle and premature ovarian failure. Results: Mean (±SD) patient age was 43 ± 4 years. Both serum FSH levels and serum E2 significantly reduced after treatment from 29.0 pg/ml to 18.0 pg/ml; p<0.0001 and from 65.6 pg/ml to 47.2 pg/ml; p= 0.034 respectively. None of the 179 women reported any complications post operatively. After PRP, 17/179 (9.49%) women became pregnant. Conclusion: The results of our observational study revealed that PRP intra-οvarian injection is associated with improved function of ovarian tissue. Future further randomized clinical trials in this field are needed to shed light in the use of PRP in ovarian rejuvenation.
Highlights
Prognosis infertility patients received intra-ovarian. Both serum follicle stimulation hormone (FSH) levels and serum E2 significantly injection of Platelet-rich plasma (PRP) followed by In Vitro Fertilization reduced after treatment from 29.0 pg/ml to 18.0 (IVF) with their own oocytes [2]
Considering the angiogenic composition of the ovary and the pivotal influence of platelet-derived growth factors on vascular activation and stabilization, treatment with autologous PRP may be viewed as the enabler of ovarian tissue regeneration [8]
As ovarian PRP treatment is a new practice, the clinical evidence on its benefits is still preliminary. This retrospective study was conducted to determine the effects of intra-ovarian PRP injection on the ovarian stimulation outcomes in women referring to an IVF center
Summary
Inclusion criteria included women over the age of 35 with at least one ovary with a history of infertility, hormonal abnormalities, absence of menstrual cycle and premature ovarian failure. FSH, estradiol (E2), luteinizing hormone (LH) and anti-Müllerian hormone (AMH) levels were determined on an unspecified day prior to initiating PRP treatment. After activated PRP injection was bilaterally completed, careful ultrasound assessment of the pelvis was performed to observe vascular integrity and absence of free pelvic fluid. Follow-up of all cases was performed during the first menstrual cycle post PRP treatment. This was reported for all cases within the subsequent calendar month Hormone levels following PRP treatment were determined on the second or the third day of the subsequent menstrual cycles, consecutively for six months. The hormone levels were tested every 31-32 days; normal values being FSH
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
